Inventor · disambiguated record
John C. Byrd
Also filed as: BYRD JOHN · BYRD JOHN C
17 granted patents·33 pending applications·230 citations·filing 1999–2024
94Inventor score
Files withOHIO STATE INNOVATION FOUNDATION15PHARMACYCLICS LLC13BYRD JOHN C4UNIV OHIO STATE RES FOUND3UNIV OHIO STATE2
Top patents by PatentIndex Score
50 records- 0197US8119101B2Anti-CD74 immunoconjugates and methods of useBYRD JOHN C·Filed 2010·Granted Feb 21, 2012·92 cites·34 claims
- 0295US10357514B2Treatment of cancer using anti-CD19 Chimeric Antigen ReceptorUNIV PENNSYLVANIA·Filed 2015·Granted Jul 23, 2019·18 cites·45 claims
- 0394US10695350B2Methods of treating and preventing graft versus host diseasePHARMACYCLICS LLC·Filed 2019·Granted Jun 30, 2020·6 cites·8 claims
- 0493US9795604B2Methods of treating and preventing graft versus host diseasePHARMACYCLICS LLC·Filed 2014·Granted Oct 24, 2017·19 cites·55 claims
- 0593US8309768B2FTY720-derived anticancer agentsCHEN CHING-SHIH·Filed 2011·Granted Nov 13, 2012·9 cites·16 claims
- 0692US8846002B2Anti-CD74 immunoconjugates and methods of useUNIV OHIO STATE·Filed 2013·Granted Sep 30, 2014·8 cites·29 claims
- 0791US10463668B2Methods of treating and preventing graft versus host diseasePHARMACYCLICS LLC·Filed 2017·Granted Nov 5, 2019·8 cites·4 claims
- 0891US9717731B2TEC family kinase inhibitor adjuvant therapyPHARMACYCLICS LLC·Filed 2013·Granted Aug 1, 2017·14 cites·6 claims
- 0988US2025345335A1Methods of treating and preventing graft versus host diseasePHARMACYCLICS LLC·Filed 2024·Application pending·0 cites
- 1086US9885086B2Phospholipase C gamma 2 and resistance associated mutationsPHARMACYCLICS LLC·Filed 2015·Granted Feb 6, 2018·8 cites·56 claims
- 1185US2024293408A1Methods of treating and preventing graft versus host diseasePHARMACYCLICS LLC·Filed 2023·Application pending·0 cites
- 1284US6841565B1Treatment of patients with chronic lymphocytic leukemiaUNIV OHIO STATE·Filed 2003·Granted Jan 11, 2005·26 cites·8 claims
- 1383US11999697B2Methods and compositions for inhibition of dihydroorotate dehydrogenaseOHIO STATE INNOVATION FOUNDATION·Filed 2021·Granted Jun 4, 2024·1 cites·20 claims
- 1481US8367037B2Anti-CD74 immunoconjugates and methods of useIMMUNOMEDICS INC·Filed 2012·Granted Feb 5, 2013·2 cites·27 claims
- 1579US2023097340A1Methods of treating and preventing graft versus host diseasePHARMACYCLICS LLC·Filed 2022·Application pending·0 cites
- 1678US11312686B2Methods and compositions for inhibition of dihydroorotate dehydrogenaseOHIO STATE INNOVATION FOUNDATION·Filed 2019·Granted Apr 26, 2022·1 cites·19 claims
- 1777US8318812B2Therapeutic agents for the treatment of lymphoid malignanciesBYRD JOHN C·Filed 2007·Granted Nov 27, 2012·1 cites·11 claims
- 1871US2021121463A1Methods of treating and preventing graft versus host diseasePHARMACYCLICS LLC·Filed 2020·Application pending·0 cites
- 1971US2024294477A1Methods and compositions for inhibition of dihydroorotate dehydrogenaseOHIO STATE INNOVATION FOUNDATION·Filed 2024·Application pending·0 cites
- 2070US8633161B2Therapeutic agents for the treatment of leukemiaPERROTTI DANILO·Filed 2006·Granted Jan 21, 2014·2 cites·5 claims
- 2166US2025207202A1Methods and compositions for identifying hox gene signatures to assign specific and effective therapies in acute myeloid leukemia and other cancersOHIO STATE INNOVATION FOUNDATION·Filed 2023·Application pending·0 cites
- 2263US9044474B2Compositions and methods for increasing drug efficacy in cancerBYRD JOHN C·Filed 2011·Granted Jun 2, 2015·1 cites·10 claims
- 2362US2019388471A1Treatment of cancer using anti-cd19 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2462US2020147084A1Tec family kinase inhibitor adjuvant therapyPHARMACYCLICS LLC·Filed 2019·Application pending·0 cites
- 2560US2025236607A1Cyclin-dependent kinase 9 (cdk9) degraders and methods of using thereofOHIO STATE INNOVATION FOUNDATION·Filed 2023·Application pending·0 cites
- 2659US2011027798A1Hybridization Quantitation Method for Modified Micro-RNA and -DNA Based OligonucleotidesUNIV OHIO STATE RES FOUND·Filed 2009·Application pending·0 cites
- 2759US2014371241A1Tec family kinase inhibitor adjuvant therapyPHARMACYCLICS INC·Filed 2014·Application pending·0 cites
- 2858US2025170133A1Pharmaceutical combinations and methods of use of amino-pyrrolopyrimidinone compoundMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 2957US2025270193A1Arylimidamides for use in treatment of cancersOHIO STATE INNOVATION FOUNDATION·Filed 2022·Application pending·0 cites
- 3055US2018071293A1Tec family kinase inhibitor adjuvant therapyPHARMACYCLICS LLC·Filed 2017·Application pending·0 cites
- 3154US2024325373A1Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpa therapeutic agentOHIO STATE INNOVATION FOUNDATION·Filed 2022·Application pending·0 cites
- 3253US6316435B2Combination therapy for lymphoproliferative diseasesSUPERGEN INC·Filed 1999·Granted Nov 13, 2001·14 cites·49 claims
- 3353US2008027105A1Dosing Regimen of Flavopiridol for Treating Cancer`AVENTIS PHARMA INC·Filed 2007·Application pending·0 cites
- 3453US2005191632A1Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemiaFiled 2003·Application pending·0 cites
- 3551US2011280913A1Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related DisordersBYRD JOHN C·Filed 2009·Application pending·0 cites
- 3651US2019203297A1Phospholipase c gamma 2 and resistance associated mutationsPHARMACYCLICS LLC·Filed 2017·Application pending·0 cites
- 3749US2023303710A1Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agentOHIO STATE INNOVATION FOUNDATION·Filed 2020·Application pending·0 cites
- 3849US2023158030A1Methods and composition for treatment of covid-19 illness requiring hospitalizationOHIO STATE INNOVATION FOUNDATION·Filed 2021·Application pending·0 cites
- 3948US2021162065A1Multi-functional cancer drug delivery nanodevice for precision medicineOHIO STATE INNOVATION FOUNDATION·Filed 2019·Application pending·0 cites
- 4046US2013123366A1Therapeutic Agents for the Treatment of Lymphoid MalignanciesUNIV OHIO STATE RES FOUND·Filed 2012·Application pending·0 cites
- 4146US2023109418A1Compositions for use for the inhibition of dihydroorotate dehydrogenaseOHIO STATE INNOVATION FOUNDATION·Filed 2020·Application pending·0 cites
- 4246US2024018108A1Methods and compositions for inhibition of dihydroorotate dehydrogenaseOHIO STATE INNOVATION FOUNDATION·Filed 2020·Application pending·0 cites
- 4346US2018037653A1Treatment for chronic lymphocytic leukemia (cll)XENCOR INC·Filed 2017·Application pending·0 cites
- 4446US2023089524A1Compositions for use in the inhibition of dihydroorotate dehydrogenaseOHIO STATE INNOVATION FOUNDATION·Filed 2020·Application pending·0 cites
- 4545US2018208993A1Highly sensitive methods for detecting btk resistance mutations in rna and dnaOHIO STATE INNOVATION FOUNDATION·Filed 2017·Application pending·0 cites
- 4643US2011251240A1Dosing Regimen of Flavopiridol for Treating CancerUNIV OHIO STATE RES FOUND·Filed 2010·Application pending·0 cites
- 4740US2015361504A1Biomarker for predicting response of cll to treatment with a btk inhibitorPHARMACYCLICS LLC·Filed 2015·Application pending·0 cites
- 4839US2017137516A1Treatment for chronic lymphocytic leukemia (cll)XENCOR INC·Filed 2015·Application pending·0 cites
- 4935US2017298446A1Biomarkers of bruton tyrosine kinase inhibitor resistanceOHIO STATE INNOVATION FOUNDATION·Filed 2015·Application pending·0 cites
- 5033US2018140602A1Combination of chimeric antigen receptor therapy and amino pyrimidine derivativesANGST DANIELA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John C. Byrd files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →